Literature DB >> 29076244

Intersecting disadvantage: Unpacking poor outcomes within early intervention in psychosis services.

Nev Jones1,2, Julia Godzikovskaya3, Zhen Zhao3, Anthony Vasquez3, Al Gilbert3, Larry Davidson2.   

Abstract

AIM: In order to strengthen specialized early intervention in psychosis (EIP) services, a contextually nuanced understanding of psychosocial forces driving suboptimal treatment response is critical. This study sought to examine factors driving poor outcomes through a systematic emic coding of psychosocial assessments for discharged EIP clients categorized as leaving with all treatment goals met (AG) or no treatment goals met (NG).
METHODS: Psychosocial assessments at baseline, 1 year, 2 years and discharge were extracted from an EIP research registry and systematically coded. One hundred and thirty clients met the study's inclusion criteria (72 NG, 58 AG) from a larger pool of 278. Assessments were coded, quantized and analysed using a combination of basic inferential statistics and thematic analysis.
RESULTS: Structural adversity, individual trauma, history of aggression/violence, limited insight and long treatment histories prior to EIP, were strong and significant predictors of poor client outcomes (NG), while motivation for treatment, college goals or preparedness at baseline, baseline engagement in constructive activities, social strengths, individual strengths, talents and family support strongly predicted better outcomes (AG). Race/ethnicity also significantly predicted outcome group. Analyses underscore the powerful impact of multiple converging forms of structural disadvantage, on the one hand, and individual, family and social strengths and supports on the other, in shaping clients' response to EIP treatment.
CONCLUSIONS: Findings emphasize the importance of greater empirical attention to background structural and socio-economic conditions among early psychosis clients and their multifaceted impacts and underscore the potential value of programmatic components explicitly designed to support clients from multiply disadvantaged backgrounds.
© 2017 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  early intervention in psychosis; individual trauma; mixed methods; structural adversity

Mesh:

Year:  2017        PMID: 29076244     DOI: 10.1111/eip.12508

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  5 in total

1.  Enhancing the Engagement of Immigrant and Ethnocultural Minority Clients in Canadian Early Intervention Services for Psychosis.

Authors:  Anika Maraj; Srividya N Iyer; Jai L Shah
Journal:  Can J Psychiatry       Date:  2018-08-01       Impact factor: 4.356

2.  The impact of early family contact on quality of life among non-Hispanic Blacks and Whites in the RAISE-ETP trial.

Authors:  Oladunni Oluwoye; Liat Kriegel; Karl C Alcover; Michael T Compton; Leopoldo J Cabassa; Michael G McDonell
Journal:  Schizophr Res       Date:  2020-01-03       Impact factor: 4.939

3.  Structural Disadvantage and Culture, Race, and Ethnicity in Early Psychosis Services: International Provider Survey.

Authors:  Nev Jones; Sarah Kamens; Oladunni Oluwoye; Franco Mascayano; Chris Perry; Marc Manseau; Michael T Compton
Journal:  Psychiatr Serv       Date:  2021-01-12       Impact factor: 4.157

4.  The missing voice of engagement: an exploratory study from the perspectives of case-managers at an early intervention service for first-episode psychosis.

Authors:  Rachel M Tindall; Kelly Allott; Magenta Simmons; Winsome Roberts; Bridget E Hamilton
Journal:  BMC Psychiatry       Date:  2019-10-24       Impact factor: 3.630

5.  A qualitative study exploring personal recovery meaning and the potential influence of clinical recovery status on this meaning 20 years after a first-episode psychosis.

Authors:  Donal O'Keeffe; Ann Sheridan; Aine Kelly; Roisin Doyle; Kevin Madigan; Elizabeth Lawlor; Mary Clarke
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-06-18       Impact factor: 4.328

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.